|
Design terms
|
#1
|
"randomized controlled trial (topic)"/exp
|
37,931
|
| |
#2
|
"randomized controlled trial"/exp
|
337,523
|
| |
#3
|
"randomization"/exp
|
61,698
|
| |
#4
|
"double blind procedure"/exp
|
115,032
|
| |
#5
|
[controlled clinical trial]/lim
|
511,199
|
| |
#6
|
[randomized controlled trial]/lim
|
337,523
|
| |
#7
|
"clinical trial"/exp
|
961,450
|
| |
#8
|
"clinical trial (topic)"/exp
|
73,222
|
| |
#9
|
#1 OR #2 OR #3 OR #4 OR #5 OR #6
|
1,088,520
|
| |
#10
|
singl*: ab,ti OR doubl*: ab,ti OR treb*: ab,ti OR tripl*: ab,ti AND (blind*: ab,ti OR mask*: ab,ti)
|
174,394
|
| |
#11
|
"placebo"/exp
|
236,244
|
| |
#12
|
random* AND (clinical OR control*) AND trial OR (placebo* AND ("randomly allocated" OR (allocated AND random*)))
|
504,649
|
| |
#13
|
(#7 OR #8) AND (#10 OR #11 OR #12)
|
513,722
|
| |
#14
|
#9 OR #13
|
705,098
|
|
Exclusion terms
|
#15
|
[conference review]/lim
|
3,863
|
| |
#16
|
"case report":ab,ti
|
256,868
|
| |
#17
|
[review]/lim
|
2,026,389
|
| |
#18
|
[letter]/lim
|
827,115
|
| |
#19
|
"phase 1 clinical trial"/exp
|
24,619
|
| |
#20
|
[short survey]/lim OR "historical article": ab,ti
|
514,714
|
| |
#21
|
"systematic review": ab,ti
|
78,920
|
| |
#22
|
"clinical review": ab,ti
|
3,904
|
| |
#23
|
#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
|
3,628,070
|
| |
#24
|
#14 NOT #23
|
424,301
|
|
Rx terms
|
#25
|
"drug therapy"/exp/mj
|
574,153
|
| |
#26
|
"treatment response"/exp/mj
|
2,763
|
| |
#27
|
"treatment outcome"/exp/mj
|
28,936
|
| |
#28
|
"drug efficacy"/exp/mj
|
153,753
|
| |
#29
|
"outcome assessment"/exp/mj
|
9,603
|
| |
#30
|
chemothera* OR ("drug"/exp/mj AND thera*) OR antineoplastic* OR palliat* OR standar* NEAR/2 care OR support* NEAR/2 care OR "best supportive care" OR best?support* NEXT/2 care
|
1,895,030
|
| |
#31
|
"radiotherapy"/exp
|
367,367
|
| |
#32
|
#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
|
2,609,134
|
| |
#33
|
#23 AND #31
|
88,937
|
|
Disease terms
|
#34
|
((lung$ OR pulmon$) NEAR/5 (adenocarcinom$ OR squamous OR "large cell" OR "non-small cell")): ab,ti
|
44,817
|
| |
#35
|
"lung non small cell cancer"/exp
|
52,027
|
| |
#36
|
metastatic: ab,ti
|
181,820
|
| |
#37
|
advanced: ab,ti
|
320,393
|
| |
#38
|
stage 3: ab,ti
|
61
|
| |
#39
|
"Stage 3": ab,ti
|
8,708
|
| |
#40
|
stage 4: ab,ti
|
32
|
| |
#41
|
"stage 4": ab,ti
|
5,270
|
| |
#42
|
stage iii: ab,ti
|
30
|
| |
#43
|
"stage iii": ab,ti
|
31,468
|
| |
#44
|
stage iv: ab,ti
|
41
|
| |
#45
|
"stage iv": ab,ti
|
20,205
|
| |
#46
|
"stage iii/iv": ab,ti
|
6
|
| |
#47
|
"stage iii/iv": ab,ti
|
4,552
|
| |
#48
|
"stage iiib/iv": ab,ti
|
2
|
| |
#49
|
"stage iii/iva": ab,ti
|
1
|
| |
#50
|
stage* iii: ab,ti
|
32
|
| |
#51
|
stage* iii*: ab,ti
|
49
|
| |
#52
|
stage* iv: ab,ti
|
41
|
| |
#53
|
stage* iv*: ab,ti
|
52
|
| |
#54
|
stage iii*: ab,ti
|
47
|
| |
#55
|
stage iv*: ab,ti
|
46
|
| |
#56
|
inoperable: ab,ti
|
12,989
|
| |
#57
|
in* operable: ab,ti
|
13,465
|
| |
#58
|
unresectable: ab,ti
|
15,735
|
| |
#59
|
non* resectable: ab,ti
|
1,208
|
| |
#60
|
late* stage: ab,ti
|
84
|
| |
#61
|
late: ab,ti AND stage: ab,ti
|
41,346
|
| |
#62
|
metast*: ab,ti OR advance*: ab,ti
|
900,959
|
| |
#63
|
relaps* OR recurr* OR unresect* OR non?resect* OR in?operable OR non?operable OR un?operable OR advanc* OR metasta* OR late NEAR/2 stage
|
1,895,338
|
| |
#64
|
#34 OR #35
|
61,621
|
| |
#65
|
#36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63
|
1,943,775
|
| |
#66
|
#64 AND #65
|
33,907
|
| |
#67
|
#33 AND #66
|
2,689
|
|
Language and year
|
#68
|
[1995–2013]/py AND [english]/lim
|
12,998,680
|
|
Final
|
#69
|
#67 AND #68
|
2,901
|
